Remimazolam and serious adverse events: A scoping review
Study context
- Population
- Patients receiving remimazolam for sedation or anaesthesia36 case reports
- Participants
- 6,740 patients · 73 trials
- Outcome
- Serious adverse events
Pooled result
As reported in the abstract
Hypotension (cases)
911
Delayed emergence (cases)
68
Anaphylaxis (cases)
10
Re-sedation (cases)
8
Further pooled results
- Higher BMI, older age and low plasma albumin are risk factors for delayed emergence
Original publication
Remimazolam and serious adverse events: A scoping review. Eur J Anaesthesiol. Published 18 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →